Tests a ketone ester supplement in adults with type 2 diabetes
Compares a ketone ester supplement with a placebo for heart function in adults with diabetes.
Key facts
- Who runs it
- Ohio State University
- Where
- Columbus, United StatesSee the site
- Trial code
- Registry title
- Effects of Ketone Ester Consumption on Exercise Tolerance and Cardiac Function
- Status
- Recruiting
- People taking part
- 30 people, planned
- Started
- 6 Jun 2023
- Expected to end
- 31 Aug 2027
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Ketone Ester Acute
- Placebo Acute
- Record updated
- 3 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 80 with type 2 diabetes and a BMI of 25 or more, who are on stable treatment. It tests a ketone ester supplement against a placebo.
- Age
- 18 to 80 years
- Sex
- All sexes can join.
- Disease stage
- Type 2 diabetes (type II diabetes mellitus). BMI of 25 or more.
- Earlier treatment
- Medical therapy stable for at least 1 month. Oral diuretic dose must be stable for 1 week before randomization. A person cannot be on a low-carb diet now (30-day washout needed).
Main reasons for not taking part
- Pregnant, breast-feeding, or planning pregnancy during the trial
- Type 1 diabetes or past diabetic ketoacidosis
- Pacemaker, defibrillator or other metal implants that are not safe in MRI; claustrophobia
- Severe kidney disease with eGFR<30 ml/kg/1.73m2
- Allergy to test supplement ingredients, or lactose intolerance
The registry criteria, word for word
Show all 29 criteriaShow less
Who can take part
- Age ≥ 18 years old and ≤ 80 years old
- Type II Diabetes Mellitus
- Stable medical therapy for at least 1 months as determined by the treating physician (no plan to change between the two testing sessions)
- Dose of oral diuretics changes allowed, but must be stable for 1 week prior to randomization
- Body Mass Index (BMI) ≥ 25
- Ability to participate in exercise treadmill testing (only if CPET is performed)
- Ability to sign written consent
Who cannot take part
- Other metallic implants/aneurysm clips that are contraindicated in MRI
- Prior diagnosis of oxygen dependent pulmonary disease
- Major surgery (major according to the investigator's assessment) performed within 90 days prior to screening, or major scheduled elective surgery (e.g. hip replacement) within 90 days after screening
- Gastrointestinal surgery or gastrointestinal disorder that might interfere with supplement consumption. Prior bariatric surgery allowed if weight-stable for past 3 months
- Current enrolment in another investigational device or drug study or completion within <30 days of a trial of another investigational device or drug study
- The subject cannot currently be on a low-carb diet plan. 30-day washout would be required
- Known allergy or sensitivity to Gadolinium based contrast agents
- Implanted pacemaker, cardioverter defibrillator, cardiac resynchronization therapy, left ventricular assist device
- Type I diabetes
- History of diabetic ketoacidosis
- Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of the uterine cervix, or low-risk prostate cancer (subjects with pre-treatment prostate-specific antigen levels of <10 ng/mL, and biopsy Gleason scores of ≤6 and clinical stage T1c or T2a)
- Presence of any disease other than diabetes that results in a life expectancy of <1 year (in the opinion of the investigator)
- Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, will make the subject unlikely to fulfil the trial requirements or complete the trial
- Any other clinical condition that might jeopardize subject safety during participation in this trial or prevent the subject from adhering to the trial Protocol
- Allergy to test article ingredients, or lactose intolerance
- History of severe kidney disease with eGFR<30 ml/kg/1.73m2
- Acute or chronic liver disease, defined by serum levels of transaminases or alkaline phosphatase more than three times the upper limit of normal at screening
- Women who are pregnant, current breast-feeding, or have intention to become pregnant while in the trial
- Claustrophobia
- Body Mass Index (BMI) < 25
- Unable or unwilling to follow guidelines of assigned supplement group
- Refusal to consent
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Where in United States
- The Ross Heart HospitalColumbus, United StatesContact: Debbie ScandlingTaking people
About the trial
What the trial wants to find out
This study is being done to evaluate how a ketone ester (KE) supplement affects heart function and health in people with diabetes compared to a placebo supplement (made with standard food ingredients that do not contain ketone esters).
The 2 groups in the trial
- Keto Ester AcuteTreatment being tested
This arm will provide a Ketone Ester supplement + a meal for consumption.
Treatment: Ketone Ester Acute
- Placebo AcutePlacebo, for comparison
This arm will provide a Placebo beverage + a meal for consumption.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Effects of Acute and Chronic Ketone Ester Consumption on Exercise Tolerance and Cardiac Function in Subjects With Diabetes
- Plain-language title
- Tests a ketone ester supplement in adults with type 2 diabetesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06078683, who can take part
- Record updated
- 3 April 2026